Alprostadil Attenuates Myocardial Ischemia/reperfusion Injury by Promoting Antioxidant Activity and Enos Activation in Rats.

Liping Zhang,Ying Zhang,Xiaofeng Yu,Huali Xu,Dayuan Sui,Xuezhong Zhao
DOI: https://doi.org/10.1590/s0102-865020180120000004
2018-01-01
Acta Cirúrgica Brasileira
Abstract:PURPOSETo investigate the effect of alprostadil on myocardial ischemia/reperfusion (I/R) in rats.METHODSRats were subjected to myocardial ischemia for 30 min followed by 24h reperfusion. Alprostadil (4 or 8 μg/kg) was intravenously administered at the time of reperfusion and myocardial infarct size, levels of troponin T, and the activity of creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH) in the serum were measured. Antioxidative parameters, nitric oxide (NO) content and phosphorylated endothelial nitric oxide synthase 3 (p-eNOS) expression in the left ventricles were also measured. Histopathological examinations of the left ventricles were also performed.RESULTSAlprostadil treatment significantly reduced myocardial infarct size, serum troponin T levels, and CK-MB and LDH activity (P<0.05). Furthermore, treatment with alprostadil significantly decreased malondialdehyde (MDA) content (P<0.05) and markedly reduced myonecrosis, edema and infiltration of inflammatory cells. Superoxide dismutase and catalase activities (P<0.05), NO level (P<0.01) and p-eNOS (P<0.05) were significantly increased in rats treated with alprostadil compared with control rats.CONCLUSIONThese results indicate that alprostadil protects against myocardial I/R injury and that these protective effects are achieved, at least in part, via the promotion of antioxidant activity and activation of eNOS.
What problem does this paper attempt to address?